Akebia Therapeutics Inc. (AKBA)

AKBA trades at $2.83, 41.5% above the near-term max pain of $2 expiring Oct 17, 2025 (11 days). Expect downward pressure as dealers benefit from price declining toward max pain. Max pain is rising across expirations ($1-$2.5), reflecting growing call interest at higher strikes. Key magnetic zone at 3 where 4 expirations converge. High dispersion in max pain levels suggests competing forces and potential volatility.

Max pain for AKBA shows an upward trend from 1 to 2.5, suggesting bullish positioning in longer-dated options. The 69% spread signals divergent expectations across timeframes. Most levels below 2.83 may cap rallies. Strong magnetic level at 3 (4 expirations). Weekly expirations influence price 2-3 days before expiry; monthlies throughout their final week.